Pfizer's Paxlovid has received a nod from the US Food and Drug Administration's (FDA's) Antimicrobial Drug Advisory Committee for use in mild-to-moderate cases of COVID-19 in adults. The 16-1 vote came after Pfizer's previous request for full approval hit a roadblock last year when the agency extended the review period.
According to , “If granted full approval, Paxlovid's EUA will remain in place so that adolescents 12 years and older can continue to be treated with the drug. In the US, more than 10 million treatment courses of Paxlovid have been prescribed to date, according to Pfizer.”
To read more, click here.
(Source: Endpoints News, March 16th, 2023)
